Among patients experiencing chronic graft-versus-host disease (cGVHD), the transition of treatment with Niktimvo (axatilimab) ...
The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may ...
To access the event by phone, please dial 1-877-317-6789 from the U.S. and Canada or 1-412-317-6789 internationally and ask to be joined into the Rezolute call. The live webcast can be accessed on the ...
A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...
FRIDAY, Dec. 12, 2025 (HealthDay News) — Less might be more when it comes to immunotherapy treatment of melanoma, a new study ...
A late-breaking presentation at the American Society of Hematology (ASH) 2025 meeting revealed promising phase 3 findings for ...
The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...
Patients with immune thrombocytopenia (ITP) who received a first-in-class investigational drug in addition to standard ...
Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk ...
Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned ...
Rezolute sinks after its Phase 3 congenital hyperinsulinism trial showed no statistically significant benefit for ersodetug despite favorable safety data.
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback